Completed dosing of 115 participants in a bioavailability and bioequivalence (BA/BE) clinical trial in Australia for IHL-42X, an investigational treatment for obstructive sleep apnea in July 2024.
Lastly, IHL-675A, a combination of cannabidiol and hydroxychloroquine sulfate, targets inflammation and is in an Australian Phase 2 trial for rheumatoid arthritis. The company's forward-looking ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback